Skip to content

Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma

Clinicopathological Characteristics of Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma Without Completion Thyroidectomy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05968196
Acronym
HCC and FTC
Enrollment
221
Registered
2023-08-01
Start date
2000-01-01
Completion date
2023-03-31
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huerthle Cell Carcinoma

Brief summary

The goal of this retrospective study is to evaluate in patients with HCC and FTC who underwent lobectomy. The main questions it aims to answer are: * The necessity of completion thyroidectomy based on the clinicopathological characteristics * Prognosis Participants underwent thyroid lobectomy Researchers compared HCC and FTC groups to see the prognosis after lobectomy.

Detailed description

Background The prognosis of Hürthle cell carcinoma (HCC) and follicular thyroid carcinoma (FTC) is poorly understood. These types of cancers are usually confirmed after diagnostic lobectomy. We aimed to evaluate the clinicopathological characteristics and prognoses of patients with HCC and FTC who did not undergo completion thyroidectomy. Materials and Methods We screened 221 patients diagnosed with FTC or HCC after thyroid lobectomy at Yonsei Severance Hospital between January 2000 and December 2020. After excluding patients who underwent complete thyroidectomy, 184 patients with FTC and 37 patients with HCC were included.

Interventions

None listed

Sponsors

The Catholic University of Korea
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Follicular thyroid carcinoma * Hurthle cell carcinoma * Lobectomy

Exclusion criteria

* Completion thyroidectomy * Total thyroidectomy

Design outcomes

Primary

MeasureTime frameDescription
Disease-free survival (DFS)From January 2000 to March 2023a comparison of disease-free survival (DFS) between FTC and HCC groups

Secondary

MeasureTime frameDescription
TNM stageFrom January 2000 to March 2023a comparison of TNM stage between FTC and HCC groups

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026